Celltrion Healthcare Canada Limited announced yesterday that Health Canada granted a notice of compliance for Remsima SC®, an infliximab biosimilar of J& J’s Remicade®, for the treatment of adult patients with rheumatoid arthritis.
Celltrion Senior Vice President Jovan Antunovic said the company is “delighted to bring the first subcutaneous form of infliximab to patients, payers and clinicians in Canada.” The press release indicates that the company expects a self-administered infliximab product will make treatment with the drug more convenient for patients.
